Category: Metabolic Disorders
-
From gut resets to microbiome rejuvenation: DDW 2026 highlights transformative approaches to digestive health
An endoscopic procedure that maintains weight loss after stopping GLP-1 drugs, the double hit of stress and late-night eating on gut health, rising rectal cancer deaths in millennials, and youthful microbiome transplants that prevent liver cancer.
-
Patients open to non-GLP-1 drugs after education, survey finds
A survey finds that while most patients remain unfamiliar with obesity treatments beyond GLP-1s, comprehensive education about alternatives significantly shifts attitudes toward personalized care.
-
ACC26: Amgen’s Repatha cuts first major CV event risk by 31%
New data show Repatha significantly reduces first heart attacks and strokes in high-risk patients without known significant plaque buildup.
-
2025 in Review: Global biotech and funding trends
Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.
-
Rapid Nexus study challenges neuropathy as the point of no return
New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.
-
Genesipre’s rare disease therapy gets orphan drug status in the US and Europe
The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).
-
SweetBio’s honey-based bandage saving limbs and closing wounds
The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.
-
Rapid Nexus charts a new path for chronic wounds
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.
-
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
-
FDA expands Novo Nordisk’s Rybelsus label to include cardiovascular risk reduction
The FDA has approved a new use for Novo Nordisk’s oral semaglutide, expanding its label to reduce cardiovascular risk in high-risk adults with type 2 diabetes.
-
How predictive CGM data is changing diabetes care and patient confidence
Dr. Jackie Elliott shares how AI-powered CGMs improve decision-making, reduce alarm fatigue, and reshape diabetes care.
-
EASD 2025: Roche unveils CE-marked AI CGM integration
Roche executives and patient advocates underscored the announcement at a dedicated EASD media event, where they discussed the clinical relevance of predictive CGM.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.